Arca
Skip to content

Chronic plaque psoriasis

Drug research and approvals for chronic plaque psoriasis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 8 studies of chronic plaque psoriasis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 13 drug trials for it since 2013.

  • Recruiting worldwide: 8
  • Trials authorized in Canada: 13
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 8 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 13; search them all in Canada trials
Dec 20, 2019A phase 3, 8-week, parallel group, double blind, vehicle-controlled study of the safety and efficacy of arq-151 cream 0.3% administered qd in subjects with…ARQ-151 (ROFLUMILAST)Arcutis BiotherapeuticsClosed
Oct 30, 2019Multicenter, randomized, parallel-group, double-blind, placiebo-controlled (12-17 years) including a single open-label arm (6-11 years) study to evaluate the…CIMZIA (CERTOLIZUMAB PEGOL)UCBOngoing
Apr 3, 2019A multicenter, randomized, open-label study to evaluate the safe and effective use of the prefilled safety syringes or the auto-injector for the subcutaneous…BIMEKIZUMABUCB CANADA INCOngoing
Sep 4, 2018A multicenter, open-label study to assess the long-term safety, tolerability, and efficacy of bimekizumb in adult subjects with moderate to severe chronic…BIMEKIZUMABUCBClosed
Jul 11, 2018A phase 2b randomized, double-blind, placebo controlled, multi-center 12-week study with an additional 40-week follow-up assessment of efficacy, safety and…NANOBODY ANTI IL 17A/F (MSB0010841 OR M1095 OR ALX0761)BOND AVILLION 2 DEVELOPMENT LPClosed
Jun 28, 2018A phase 3, multicenter, randomized, placebo- and active comparator-controlled study evaluating the efficacy, safety, and pharmacokinetics of subcutaneously…TREMFYAJohnson & JohnsonOngoing
Jun 12, 2018A multicenter, randomized, double-blind, secukinuimab-controlled, parallel-group study to evaluate the efficacy and safety of bimekizumab in adult subjects…BIMEKIZUMAB (UCB4940)UCBOngoing
Jun 8, 2018A randomized, double-blind, placebo and active controlled multicenter trial to demonstrate efficacy of subcutaneous secukinumab compared to placeboand…COSENTYXNovartis Pharmaceuticals CorporationClosed
Mar 10, 2017A multicenter, 48-week, open-label extension study to assess the long-term safety, tolerability and efficacy of bimekizumab in adult subjects with moderate to…BIMEKIZUMABUCBClosed
Nov 9, 2016A multicenter, randomized, subject-blind, investigator-blind study to evaluate the time course of pharmacodynamic response, safety and pharmacokinetics of…UCB4940 (BIMEKIZUMAB)UCBOngoing

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.